ABSTRACT
Os estudos em biologia molecular desenvolvidos nas últimas décadas, possibilitaram grandes avanços para uma maior compreensão da carcinogênese colorretal. Na década de 80 pesquisadores descobriram uma proteína com a capacidade de aumentar a permeabilidade dos vasos sangüíneos. Inicialmente esta proteína foi denominada como fator de permeabilidade vascular. Estudos posteriores correlacionaram esta proteína com o crescimento de novos vasos sangüíneos (angiogênese), quando passou a ser chamada de fator de crescimento endotelial vascular (VEGF). A proteína VEGF tem sido apontada como o principal fator promotor da angiogênese, dentre os vários já conhecidos. Neste trabalho o objetivo foi quantificar a proteína VEGF, e correlacionar os resultados com o estadiamento tumoral em amostras de adenocarcinoma colorretal. Foram incluídos 56 adenocarcinomas colorretais, nos quais a detecção da proteína VEGF foi realizada por imunoistoquímica através da construção de uma matriz tecidual e sua quantificação com análise digital de imagens assistida por computador. Nossos resultados não evidenciaram relação estatisticamente significativa entre a expressão da proteína VEGF e o estadiamento tumoral, ou presença e número de linfonodos comprometidos. Baseado no nível de expressão da proteína VEGF não foi possível inferir a presença de linfonodos comprometidos nas amostras analisadas.
Development of studies in molecular biology over the last decades has contributed for better knowledge about colorectal carcinogenesis. An important landmark in this process was the identification of a protein with effect on vascular permeability eventually named as vascular endothelial growth factor (VEGF), which seems to be essential for the angiogenesis activation of tumor development. The aim of this study was to assess the VEGF expression and correlate to tumor staging in colorectal cancer. Surgical specimens from 56 colorectal cancer patients were analyzed by immunohistochemistry for VEGF expression using a multitissue array and a computer-assisted image system. No significant result was found between VEGF expression and tumor staging or lymph nodes metastasis. We concluded that no predictive value for lymph nodes metastasis could be demonstrated by VEGF immunostaining in this study.
Subject(s)
Humans , Colorectal Neoplasms , Immunohistochemistry , Molecular Biology , Neoplasm Staging , Vascular Endothelial Growth Factor Receptor-1ABSTRACT
Background and purpose: Herpesvirus-associated ubiquitin-specific protease (HAUSP) is a new deubiquitinating enzyme that was recently discovered. It has been demonstrated that HAUSP could deubiquitinate p53 both in vitro and in vivo. These results suggested that HAUSP might act as a tumor suppressor through the stabilization of p53 protein. The aim of this study was to investigate the expression of HAUSP in breast carcinoma, and its association with p53 protein as well as their relationship to prognosis. Methods: The expression of HAUSP mRNA was detected by real-time PCR. HAUSP protein and p53 protein were detected by immunohistochemistry with EnVision system in breast carcinoma tissues and noncancerous tissues. The relationship between their expressions and clinical pathological parameters were analyzed. Results: The expression of HAUSP mRNA was significantly lower in breast cancer tissue than noncancerous tissue (1.85±0.04 vs. 2.74±0.03, P<0.01). The positive rates of HAUSP protein were significantly lower in breast cancer tissue in noncancerous tissue (59.4% vs. 75.0%, P<0.01), and expression of HAUSP protein had no significant correlation with the clinical pathological parameters. There was no significant correlation between HAUSP and p53 protein (P>0.05). The expression of HAUSP mRNA was positively associated with that of HAUSP protein (P<0.01). There was no significant correlation between HAUSP and p53 protein. DFS of patients with both HAUSP positive and p53 negative was significant higher than the controls (P<0.01). Conclusion: Down-regulation of HAUSP protein and HAUSP mRNA in breast carcinoma indicated that HAUSP gene might correlated to tumor carcinogenesis. In addition, the simultaneous evaluation of both HAUSP expression and p53 expression status may be helpful to evaluate the prognosis of breast cancer patients.
ABSTRACT
Background and purpose:Brain is one of the most common sites for distant metastasis in patients with non-small cell lung cancer,and the prognosis of patients with brain metastasis is usually dismal.The purpose of this retrospective study is to document the relationship between the prognosis of lung cancer patients with brain metastasis and the expressions of p53,nm23 and VEGF in resected lung cancer tissues.Methods:Ninety-two patients who were definitively treated with surgery for non-small cell lung cancer but lately developed brain metastasis between 1997 and 2005 were identified in our institution.Their clinical data were retrieved and retrospectively reviewed.All pathological specimens of their resected lung cancer were examined for the expressions of p53,nm23 and VEGF by immunohistochemical staining.The association between the treatment outcome and the expression of the above mentioned biomarkers were analyzed.Results:The median survival time(MST) of patients with p53(+) versus p53(-) was 11.0 versus 11.9 month,respectively.The 1,2,and 3-year overall survival rates were 45.71%,22.86%,and 18.29% respectively for p53(+) patients,and 49.55%,16.12%,and 8.89% respectively for p53(-) patients(P=0.5179);The MST of patients with nm23(+) versus nm23(-) was 13.0 versus 10.1 month,respectively.The 1,2,and 3-year overall survival rates were 54.20%,21.51%,and 16.45% respectively for nm23(+) patients,and 32.0%,12.0%,and 4.0% respectively for nm23(-) patients(P=0.1075);The MST of patients with VEGF(+) versus VEGF(-) was 10.5 versus 12.2 months,respectively.The 1,2,and 3 year overall survival rates were 42.20%,0,and 0 respectively for VEGF(+) patients,and 50.0%,25.41%,and 16.57% respectively for VEGF(-) patients(P=0.0231).Conclusions:VEGF was a significant adverse prognostic factor for patients with non-small cell lung cancer who developed brain metastasis.Lung cancer patients whose tumor tissue demonstrated positive VEGF expression had reduced overall survival rates at 1,2,and 3 years after surgery.The expression of p53 and nm23 are not significantly associated to the prognosis of this group of patients.
ABSTRACT
LSAB immunohistochemistry and digoxin-labeled in situ hybridization methods were used to detect the expression of EGFR and TGF-a and the transcription of EGFR-mRNA in human renal cell carcinoma (RCC) tissues. The expression rate of EGFR and TGF-α in 46 cases of human RCC tissues were significantly higher than that in 38 cases of corresponding autologous normal kidney tissues (EGFR.. 53. 4 % vs 21.0 %;TGF-α: 39. 1 /% vs 13. 2 %, P＜0. 05). Both EGFR and TGF-α were simultaneously overexpressed in some cases of RCC tissues. No relationship existed between EGFR or TGF-α and the RCC staging and grading. The positive rate of transcription EGFR-mRNA in 25 cases of RCC tissues was significantly higher than that in 20 cases of corresponding autologous normal kidney tissues (44 % vs 15 %, P＜0. 05). The above findings demonstrated that RCC tissues overexpressed EGFR and TGF-αand overtranscribed EGFR-mRNA. The overexpressed EGFR and TGF-α might contribute to the growth and development of RCC by taking part in the autocrine growth loop in RCC.